🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Cohort Study on Neuroimmune Diseases in the Reproductive Age

Recruitingn/aAges 20 Years - 55 YearsFemaleThird Affiliated Hospital, Sun Yat-Sen University
NCT07653984 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of neuroimmune diseases during pregnancy is particularly important. This study included a follow-up period of up to five years in patients with pregnancy-associated neuroimmune disorders. Data collected included relapse frequency, symptomatology, imaging findings, treatment regimens, peripheral blood profiles, EDSS scores, and MRI results. In addition, maternal drug concentrations, postpartum relapse rates, and neonatal development were monitored after delivery. Following the successful completion of the five-year follow-up, the research team plans to continue the prospective epidemiological study with ten-year follow-up phases. The aim of this study is to generate detailed clinical data on pregnancy-associated autoimm

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient Group: A total of fifty participants are expected to be enrolled. 1. Women aged 20-55 years with childbearing potential. 2. Voluntary informed consent. 3. Availability of complete personal information. 4. A confirmed diagnosis of neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), autoimmune encephalitis, myasthenia gravis, Guillain-Barré syndrome, or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Healthy Control Group: A total of fifty healthy women are expected to be included. 1. Age- and sex-matched women of childbearing age with plans for pregnancy 2. Voluntary informed consent. 3. Availability of complete personal information. Exclusion Criteria: * Patient Group: 1. Patients with an undetermined or unconfirmed diagnosis. 2. Incomplete personal information that cannot be obtained through follow-up. 3. Participants who voluntarily withdrew from the study and revoked informed consent. Healthy Control Group: 1. Individuals diagnosed with neuroimmune-related disorders. 2. Incomplete personal information that cannot be obtained through follow-up. 3. Participants who voluntarily withdrew from the study and revoked informed consent.
💊

What it tests

  • Not listed
📍

Where

1 site
The Third Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy